Psychoactive drugs

DGAP-News: Cannovum AG starts European cannabis expansion with founding of Cannovum Iberia LDA

Retrieved on: 
Monday, September 6, 2021

Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has started its European cannabis expansion with its subsidiary, Cannovum Health eG.

Key Points: 
  • Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has started its European cannabis expansion with its subsidiary, Cannovum Health eG.
  • The first step for this was founding Cannovum Iberia LDA, a joint venture between Cannovum and Portuguese entrepreneurs from the cannabis industry.
  • Cannovum Iberia will initially distribute cannabis pharmaceuticals to pharmacies in Portugal.
  • "We have reached the first milestone and successfully completed the founding process of Cannovum Iberia LDA.

Global Medical Cannabis Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021

Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.

Key Points: 
  • Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family.
  • Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions.
  • Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
  • As a result, increasing disposable incomes are projected to create a positive impact on the demand for medical cannabis.

Let There Be Carnage: Sink Your Teeth Into New G FUEL "Black Ooze" And "Red Ooze" Energy Drinks

Retrieved on: 
Wednesday, August 4, 2021

In reality, there's only one way to get your tendrils on these two new G FUEL flavors: pre-order your limited-edition G FUEL Black Ooze and Red Ooze at gfuel.com through August 6th while symbiotes last.

Key Points: 
  • In reality, there's only one way to get your tendrils on these two new G FUEL flavors: pre-order your limited-edition G FUEL Black Ooze and Red Ooze at gfuel.com through August 6th while symbiotes last.
  • Each 16 oz G FUEL Black Ooze and Red Ooze Can has zero calories and contains 300 mg of caffeine.
  • Pre-order your limited-edition G FUEL Black Ooze and Red Ooze collector's boxes and tubs at gfuel.com/collections/venom before pre-orders close on August 6th.
  • As The Official Energy Drink of Esports, G FUEL provides gamers with a healthier, more performance-driven alternative to standard energy drink products.

BioHarvest Sciences Inc. Announces a CAD 4 Million Private Placement to Accelerate Its Cannabis Development Program and Production Capacity in Israel

Retrieved on: 
Wednesday, August 4, 2021

The funds will enhance the Company's cash position to:

Key Points: 
  • The funds will enhance the Company's cash position to:
    Accelerate the Company's Cannabis development program.
  • Provide for the required system upgrades for the conversion of the existing 2 Tons/year VINIA facility into a Cannabis production facility to be operational in H1/2022.
  • Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology.
  • Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes.

Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK

Retrieved on: 
Wednesday, August 4, 2021

Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions.

Key Points: 
  • Awakn Clinics London will join Awakn Clinics Bristol as the only clinics in the world providing evidence backed Ketamine-Assisted Psychotherapy for Alcohol Use Disorder.
  • Awakn Clinics London, a 5,000 square-foot, 8 treatment room clinic, will deliver psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies.
  • Awakn Clinics London will be owned and operated by Awakn and will be led by on-site psychiatrists.
  • Awakn Clinics London will be the second of three Awakn clinics to open this year in the UK.

From Red Gold to Olympic Gold: Seedo Corp. Seeks Solutions for Athletes and More

Retrieved on: 
Wednesday, August 4, 2021

Similar to the approach of the indoor cannabis industry, Seedo hopes to be able to enhance the medicinal properties of this unique herb for use in pharmaceutical and nutraceutical applications.

Key Points: 
  • Similar to the approach of the indoor cannabis industry, Seedo hopes to be able to enhance the medicinal properties of this unique herb for use in pharmaceutical and nutraceutical applications.
  • With mental health entering the cultural conversation, Seedo Corp. hopes saffron will be seen as part of a new nature-based approach to mental health.
  • "Seedo Corp is committed to developing breakthroughs rooted in nature that are effective and safe for athletes and everyday consumers alike."
  • Seedo Corp hopes to expand the billion dollar saffron market by producing a reliable, consistent and large-scale supply of the spice.

Sunrise Recovery Ranch Awarded $100,000 Grant to Help Fight Opioid Crisis

Retrieved on: 
Wednesday, August 4, 2021

RIVERSIDE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sunrise Recovery Ranch, one of Californias leading addiction and mental health disorder treatment facilities, has received a grant to provide treatment for lower-income individuals who have been impacted by the nations ongoing opioid crisis.

Key Points: 
  • RIVERSIDE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sunrise Recovery Ranch, one of Californias leading addiction and mental health disorder treatment facilities, has received a grant to provide treatment for lower-income individuals who have been impacted by the nations ongoing opioid crisis.
  • The MAT Access Points Project is providing funding to a network of organizations throughout California to address the opioid crisis by supporting prevention, education, stigma reduction, treatment, and recovery services for people who are struggling with opioid use disorder and other substance use disorders.
  • As a society, we need to recognize that the opioid epidemic in this country will not end without profound, inventive solutions, Sunrise Recovery Ranch CEO Marlon Rollins said.
  • Sunrise Recovery Ranch offers MAT as part of its comprehensive services and evidence-based treatment options.

New poll shows a strong base of Canadians overwhelmingly support controlled legal access to psilocybin-assisted therapy; Canadian Psychedelic Association responds with Memorandum of Regulatory Approval (MORA)

Retrieved on: 
Wednesday, August 4, 2021

With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.

Key Points: 
  • With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.
  • Dr. Kryskow has witnessed firsthand what legal access to psychedelic medicine can do for Canadians in need of new treatment options.
  • Cory Firth, the Executive Director of the Canadian Psychedelic Association is confident the proposed amendments will continue our collaborative effort with Health Canada.
  • 82% of Canadians polled support or somewhat support approval for allowing the use of psilocybin-assisted therapy.

US Cannabis Council Elects Akerna CEO, Jessica Billingsley, as Board Chair

Retrieved on: 
Wednesday, August 4, 2021

Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.

Key Points: 
  • Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.
  • To do so, USCC works hand-in-hand with Congressional leaders in Washington, DC and throughout the country to advance cannabis reform.
  • Billingsley was unanimously elected as chair due to her leadership experience in the cannabis industry.
  • "Her extensive background working in the cannabis industry and with government will greatly assist USCC in reforming cannabis policy and advancing an equitable, well-regulated cannabis industry in all fifty states.

Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Retrieved on: 
Tuesday, August 3, 2021

San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.

Key Points: 
  • San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.
  • The conference will be held virtually on August 10-12, 2021.
  • Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN) program for chronic pain and eating disorder indications.
  • Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.